Cytokinetics analyst coverage

Author: rykx

August undefined, 2024

WebMar 3, 2024 · Following the latest upgrade, the current consensus, from the 13 analysts covering Cytokinetics, is for revenues of US$54m in 2024, which would reflect a stressful 43% reduction in... WebFor more in-depth coverage of Tesla Motors, ... Analyst Price Forecast Suggests 12.52% Upside. As of April 6, 2024, the average one-year price target for Tesla Motors is $203.14. The forecasts ...

Unusual Put Option Trade in Tesla Motors (TSLA) Worth …

WebOct 7, 2024 · Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised. WebApr 9, 2024 · Truist Financial initiated coverage on shares of Cytokinetics in a research note on Tuesday, December 20th. They issued a “buy” rating and a $60.00 target price for the company. Bank of America... ttl7207

Cytokinetics Reports Third Quarter 2024 Financial Results

WebApr 10, 2024 · Trevor Immelman faced the tall task of being named CBS Sports’ lead golf analyst in January, replacing Nick Faldo in the 18th tower, but he soared into this weekend’s coverage of the Masters. WebMar 1, 2024 · SOUTH SAN FRANCISCO, Calif., March 01, 2024(GLOBE NEWSWIRE) -- Cytokinetics, Incorporated(Nasdaq: CYTK) reported financial results for the fourth … WebJul 19, 2024 · The webcast can be accessed through the Investors & Media section of the Cytokinetics website at www.cytokinetics.com. The live audio of the conference call can also be accessed by telephone by dialing either (866) 999-CYTK (2985) ( United States and Canada ) or (706) 679-3078 (international) and typing in the passcode 2984784. phoenix football eden park

CYTK - Cytokinetics Inc Stock Price Quote - NASDAQ Morningstar

WebApr 12, 2024 · Wall Street Analyst Weigh In. Several brokerages recently weighed in on CYTK. Needham & Company LLC reissued a “buy” rating and issued a $58.00 target price on shares of Cytokinetics in a ... Web12 hours ago · Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cytokinetics ( CYTK – Research Report) and Neurocrine ( … ttl706WebApr 9, 2024 · CYTK has been the topic of a number of recent analyst reports. Needham & Company LLC reiterated a “buy” rating and issued a $58.00 target price on shares of Cytokinetics in a research note on ... phoenix for advisers contact number

"WebCytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class … " - Cytokinetics analyst coverage

Cytokinetics analyst coverage

Cytokinetics (CYTK) Stock Forecast & Price Target - TipRanks

WebCytokinetics was founded by pioneers in the field of muscle biology. This team of forward-thinking scientists set out a vision for translating their expertise into new insights and approaches to novel drug discovery. WebShare This: Share 2024 – Summer Analyst Internship – Financial Institutions Coverage (FIC) on Facebook Share 2024 – Summer Analyst Internship – Financial Institutions ... Financial Institutions Coverage (FIC) manages relationships with the bank’s largest institutional clients across key sectors: banks, hedge funds, asset managers ...

Did you know?

WebCytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing muscle activators and inhibitors. Investors & Media. ... Analyst Coverage. Investor FAQ. IR/Media Contacts. Corporate Governance. Information Request . Email Alerts . WebMar 31, 2024 · March 31, 2024 Cytokinetics Announces COURAGE-ALS Met Criteria for Futility at Second Interim Analysis. March 27, 2024 Cytokinetics Releases Inaugural Corporate Responsibility Report. March …

WebPer-Share Earnings, Actuals & Estimates Cytokinetics Inc. Quarterly Annual Actual Analyst Range Consensus 0.50 0.00 -0.50 -1.00 -1.50 CYTK will report Q1 earnings on … WebJan 9, 2024 · By contrast, our data suggests that other companies (with analyst coverage) in the industry are forecast to see their revenue grow 14% per year. ... We have analyst estimates for Cytokinetics ...

WebJan 7, 2024 · Royalty Pharma Extends Capital to Cytokinetics to Support the Commercial Launch of Omecamtiv Mecarbil and the Further Development of Aficamten; Royalty Pharma Purchases Royalties on Future Sales of Aficamten; Cytokinetics to Host Conference Call and Webcast Today at 8:30 a.m. ET; NEW YORK, NY and SOUTH SAN FRANCISCO, … WebApr 6, 2024 · Analyst Price Forecast Suggests 12.99% Upside As of April 6, 2024, the average one-year price target for Broadcom is $696.81. The forecasts range from a low of $589.84 to a high of $787.50.

WebMar 31, 2024 · SOUTH SAN FRANCISCO, Calif., March 31, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Data Monitoring …

WebOur Corporate Responsibility Framework. Keep Patients at the Center of our Work. Continue to embed patient centricity across all stages of our business. Maintain strong … phoenix food truck waukeshaWebFintel reports that on April 13, 2024, Baird initiated coverage of Pliant Therapeutics (NASDAQ:PLRX) with a Outperform recommendation. Analyst Price Forecast Suggests 80.40% Upside As of April 6 ... phoenix for advisers loginWebApr 11, 2024 · What analysts cover Cytokinetics? Cytokinetics has been rated by Bank of America, Cantor Fitzgerald, HC Wainwright, JMP Securities, Mizuho, Needham & Company LLC, Oppenheimer, The Goldman Sachs Group, and UBS Group in the past 90 days. Stock Ratings Reports and Tools Top-Rated Brokerages Stock Ratings Screener Free Ratings … phoenix football boxWebApr 5, 2024 · According to analysts' consensus price target of $56.21, Cytokinetics has a forecasted upside of 60.7% from its current price of $34.99. Amount of Analyst … t.tl/69seWeb17 rows · Mar 27, 2024 · PRESS RELEASES Cytokinetics, Inc. INVESTORS & MEDIA 2024 Press Releases Webcast 22nd Annual Needham Virtual Healthcare Conference … ttl 7207WebMay 24, 2024 · Below is a summary of how these 4 analysts rated Cytokinetics over the past 3 months. The greater the number of bullish ratings, the more positive analysts are … ttl7401Web2 days ago · CYTOKINETICS, INC. : Trading strategies, financial analysis, commentaries and investment guidance for CYTOKINETICS, INC. Stock Nasdaq: Nasdaq ttl 7402